Table of Contents Author Guidelines Submit a Manuscript
Journal of Immunology Research
Volume 2015, Article ID 268172, 15 pages
http://dx.doi.org/10.1155/2015/268172
Research Article

A Novel PET Imaging Using 64Cu-Labeled Monoclonal Antibody against Mesothelin Commonly Expressed on Cancer Cells

1Department of Cell Chemistry, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama 700-8558, Japan
2Department of Urology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama 700-8558, Japan
3Collaborative Research Center for OMIC, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama 700-8558, Japan
4Department of Research and Development, Ina Institute, Medical & Biological Laboratories, Co., Ltd., Ina 396-0002, Japan
5Technology Research Laboratory, Shimadzu Corporation, Kyoto 604-8511, Japan

Received 26 November 2014; Revised 14 February 2015; Accepted 19 February 2015

Academic Editor: Peirong Jiao

Copyright © 2015 Kazuko Kobayashi et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. K. Chang, I. Pastan, and M. C. Willingham, “Isolation and characterization of a monoclonal antibody, K1, reactive with ovarian cancers and normal mesothelium,” International Journal of Cancer, vol. 50, no. 3, pp. 373–381, 1992. View at Publisher · View at Google Scholar · View at Scopus
  2. R. Hassan, T. Bera, and I. Pastan, “Mesothelin: a new target for immunotherapy,” Clinical Cancer Research, vol. 10, no. 12, pp. 3937–3942, 2004. View at Publisher · View at Google Scholar · View at Scopus
  3. R. Hassan and M. Ho, “Mesothelin targeted cancer immunotherapy,” European Journal of Cancer, vol. 44, no. 1, pp. 46–53, 2008. View at Google Scholar · View at Scopus
  4. P. Argani, C. Iacobuzio-Donahue, B. Ryu et al., “Mesothelin is overexpressed in the vast majority of ductal adenocarcinomas of the pancreas: identification of a new pancreatic cancer marker by serial analysis of gene expression (SAGE),” Clinical Cancer Research, vol. 7, no. 12, pp. 3862–3868, 2001. View at Google Scholar · View at Scopus
  5. K. Baba, S. Ishigami, T. Arigami et al., “Mesothelin expression correlates with prolonged patient survival in gastric cancer,” Journal of Surgical Oncology, vol. 105, no. 2, pp. 195–199, 2012. View at Publisher · View at Google Scholar · View at Scopus
  6. R. Hassan, R. J. Kreitman, I. Pastan, and M. C. Willingham, “Localization of mesothelin in epithelial ovarian cancer,” Applied Immunohistochemistry & Molecular Morphology, vol. 13, no. 3, pp. 243–247, 2005. View at Publisher · View at Google Scholar · View at Scopus
  7. N. G. Ordóñez, “Application of mesothelin immunostaining in tumor diagnosis,” The American Journal of Surgical Pathology, vol. 27, no. 11, pp. 1418–1428, 2003. View at Publisher · View at Google Scholar · View at Scopus
  8. N. G. Ordóñez, “Value of mesothelin immunostaining in the diagnosis of mesothelioma,” Modern Pathology, vol. 16, no. 3, pp. 192–197, 2003. View at Publisher · View at Google Scholar · View at Scopus
  9. J. Tchou, L.-C. Wang, B. Selven et al., “Mesothelin, a novel immunotherapy target for triple negative breast cancer,” Breast Cancer Research and Treatment, vol. 133, no. 2, pp. 799–804, 2012. View at Publisher · View at Google Scholar · View at Scopus
  10. K. Chang and I. Pastan, “Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers,” Proceedings of the National Academy of Sciences of the United States of America, vol. 93, no. 1, pp. 136–140, 1996. View at Publisher · View at Google Scholar · View at Scopus
  11. L. A. Dainty, J. I. Risinger, C. Morrison et al., “Overexpression of folate binding protein and mesothelin are associated with uterine serous carcinoma,” Gynecologic Oncology, vol. 105, no. 3, pp. 563–570, 2007. View at Publisher · View at Google Scholar · View at Scopus
  12. D. Steinbach, M. Onda, A. Voigt et al., “Mesothelin, a possible target for immunotherapy, is expressed in primary AML cells,” European Journal of Haematology, vol. 79, no. 4, pp. 281–286, 2007. View at Publisher · View at Google Scholar · View at Scopus
  13. L. Yu, M. Feng, H. Kim et al., “Mesothelin as a potential therapeutic target in human cholangiocarcinoma,” Journal of Cancer, vol. 1, no. 1, pp. 141–149, 2010. View at Google Scholar · View at Scopus
  14. T. K. Bera and I. Pastan, “Mesothelin is not required for normal mouse development or reproduction,” Molecular and Cellular Biology, vol. 20, no. 8, pp. 2902–2906, 2000. View at Publisher · View at Google Scholar · View at Scopus
  15. Z. Tang, M. Qian, and M. Ho, “The role of mesothelin in tumor progression and targeted therapy,” Anti-Cancer Agents in Medicinal Chemistry, vol. 13, no. 2, pp. 276–280, 2013. View at Publisher · View at Google Scholar · View at Scopus
  16. J. A. A. Gubbels, J. Belisle, M. Onda et al., “Mesothelin-MUC16 binding is a high affinity, N-glycan dependent interaction that facilitates peritoneal metastasis of ovarian tumors,” Molecular Cancer, vol. 5, article 50, 2006. View at Publisher · View at Google Scholar · View at Scopus
  17. R. Hassan, C. Schweizer, K. F. Lu et al., “Inhibition of mesothelin-CA-125 interaction in patients with mesothelioma by the anti-mesothelin monoclonal antibody MORAb-009: implications for cancer therapy,” Lung Cancer, vol. 68, no. 3, pp. 455–459, 2010. View at Publisher · View at Google Scholar · View at Scopus
  18. A. Shimizu, S. Hirono, M. Tani et al., “Coexpression of MUC16 and mesothelin is related to the invasion process in pancreatic ductal adenocarcinoma,” Cancer Science, vol. 103, no. 4, pp. 739–746, 2012. View at Publisher · View at Google Scholar · View at Scopus
  19. M. C. Chang, C. A. Chen, P. J. Chen et al., “Mesothelin enhances invasion of ovarian cancer by inducing MMP-7 through MAPK/ERK and JNK pathways,” Biochemical Journal, vol. 442, no. 2, pp. 293–302, 2012. View at Publisher · View at Google Scholar · View at Scopus
  20. E. L. Servais, C. Colovos, L. Rodriguez et al., “Mesothelin overexpression promotes mesothelioma cell invasion and MMP-9 secretion in an orthotopic mouse model and in epithelioid pleural mesothelioma patients,” Clinical Cancer Research, vol. 18, no. 9, pp. 2478–2489, 2012. View at Publisher · View at Google Scholar · View at Scopus
  21. U. Bharadwaj, C. Marin-Muller, M. Li, C. Chen, and Q. Yao, “Mesothelin confers pancreatic cancer cell resistance to TNF-α-induced apoptosis through Akt/PI3K/NF-κB activation and IL-6/Mcl-1 overexpression,” Molecular Cancer, vol. 10, article 106, 2011. View at Publisher · View at Google Scholar · View at Scopus
  22. U. Bharadwaj, C. Marin-Muller, M. Li, C. Chen, and Q. Yao, “Mesothelin overexpression promotes autocrine IL-6/sIL-6R trans-signaling to stimulate pancreatic cancer cell proliferation,” Carcinogenesis, vol. 32, no. 7, pp. 1013–1024, 2011. View at Publisher · View at Google Scholar · View at Scopus
  23. M.-C. Chang, C.-A. Chen, C.-Y. Hsieh et al., “Mesothelin inhibits paclitaxel-induced apoptosis through the PI3K pathway,” Biochemical Journal, vol. 424, no. 3, pp. 449–458, 2009. View at Publisher · View at Google Scholar · View at Scopus
  24. W.-F. Cheng, C.-Y. Huang, M.-C. Chang et al., “High mesothelin correlates with chemoresistance and poor survival in epithelial ovarian carcinoma,” British Journal of Cancer, vol. 100, no. 7, pp. 1144–1153, 2009. View at Publisher · View at Google Scholar · View at Scopus
  25. M. Ho, M. Feng, R. J. Fisher, C. Rader, and I. Pastan, “A novel high-affinity human monoclonal antibody to mesothelin,” International Journal of Cancer, vol. 128, no. 9, pp. 2020–2030, 2011. View at Publisher · View at Google Scholar · View at Scopus
  26. K. Iwahori, T. Osaki, S. Serada et al., “Megakaryocyte potentiating factor as a tumor marker of malignant pleural mesothelioma: evaluation in comparison with mesothelin,” Lung Cancer, vol. 62, no. 1, pp. 45–54, 2008. View at Publisher · View at Google Scholar · View at Scopus
  27. A. M. Wu and P. D. Senter, “Arming antibodies: prospects and challenges for immunoconjugates,” Nature Biotechnology, vol. 23, no. 9, pp. 1137–1146, 2005. View at Publisher · View at Google Scholar · View at Scopus
  28. P. J. Blower, J. S. Lewis, and J. Zweit, “Copper radionuclides and radiopharmaceuticals in nuclear medicine,” Nuclear Medicine and Biology, vol. 23, no. 8, pp. 957–980, 1996. View at Publisher · View at Google Scholar · View at Scopus
  29. T. Toyota, T. Hanafusa, T. Oda et al., “A purification system for 64Cu produced by a biomedical cyclotron for antibody PET imaging,” Journal of Radioanalytical and Nuclear Chemistry, vol. 298, no. 1, pp. 295–300, 2013. View at Publisher · View at Google Scholar · View at Scopus
  30. W. P. Li, L. A. Meyer, D. A. Capretto, C. D. Sherman, and C. J. Anderson, “Receptor-binding, biodistribution, and metabolism studies of 64Cu-DOTA-cetuximab, a PET-imaging agent for epidermal growth-factor receptor-positive tumors,” Cancer Biotherapy and Radiopharmaceuticals, vol. 23, no. 2, pp. 158–171, 2008. View at Publisher · View at Google Scholar · View at Scopus
  31. R. Hassan, C. Wu, M. W. Brechbiel, I. Margulies, R. J. Kreitman, and I. Pastan, “Indium111-labeled monoclonal antibody K1: Biodistribution study in nude mice bearing a human carcinoma xenograft expressing mesothelin,” International Journal of Cancer, vol. 80, no. 4, pp. 559–563, 1999. View at Publisher · View at Google Scholar
  32. N. Scholler, N. Fu, Y. Yang et al., “Soluble member(s) of the mesothelin/megakaryocyte potentiating factor family are detectable in sera from patients with ovarian carcinoma,” Proceedings of the National Academy of Sciences of the United States of America, vol. 96, no. 20, pp. 11531–11536, 1999. View at Publisher · View at Google Scholar · View at Scopus
  33. J. Creaney, R. J. Francis, I. M. Dick et al., “Serum soluble mesothelin concentrations in malignant pleural mesothelioma: relationship to tumor volume, clinical stage and changes in tumor burden,” Clinical Cancer Research, vol. 17, no. 5, pp. 1181–1189, 2011. View at Publisher · View at Google Scholar · View at Scopus
  34. U. Bharadwaj, M. Li, C. Chen, and Q. Yao, “Mesothelin-induced pancreatic cancer cell proliferation involves alteration of cyclin E via activation of signal transducer and activator of transcription protein 3,” Molecular Cancer Research, vol. 6, no. 11, pp. 1755–1765, 2008. View at Publisher · View at Google Scholar · View at Scopus
  35. J. Fredebohm, M. Boettcher, C. Eisen et al., “Establishment and characterization of a highly tumourigenic and cancer stem cell enriched pancreatic cancer cell line as a well defined model system,” PLoS ONE, vol. 7, no. 11, Article ID e48503, 2012. View at Publisher · View at Google Scholar · View at Scopus
  36. M. Li, U. Bharadwaj, R. Zhang et al., “Mesothelin is a malignant factor and therapeutic vaccine target for pancreatic cancer,” Molecular Cancer Therapeutics, vol. 7, no. 2, pp. 286–296, 2008. View at Publisher · View at Google Scholar · View at Scopus
  37. M. Miyazawa, M. Iwahashi, T. Ojima et al., “Dendritic cells adenovirally-transduced with full-length mesothelin cDNA elicit mesothelin-specific cytotoxicity against pancreatic cancer cell lines in vitro,” Cancer Letters, vol. 305, no. 1, pp. 32–39, 2011. View at Publisher · View at Google Scholar · View at Scopus
  38. R. Hassan, Z. G. Laszik, M. Lerner, M. Raffeld, R. Postier, and D. Brackett, “Mesothelin is overexpressed in pancreaticobiliary adenocarcinomas but not in normal pancreas and chronic pancreatitis,” American Journal of Clinical Pathology, vol. 124, no. 6, pp. 838–845, 2005. View at Publisher · View at Google Scholar · View at Scopus
  39. S. Lutje, M. Rijpkema, G. M. Franssen et al., “Dual-modality image-guided surgery of prostate cancer with a radiolabeled fluorescent anti-PSMA monoclonal antibody,” Journal of Nuclear Medicine, vol. 55, no. 6, pp. 995–1001, 2014. View at Publisher · View at Google Scholar
  40. W. Ping Li, L. A. Meyer, D. A. Capretto, C. D. Sherman, and C. J. Anderson, “Receptor-binding, biodistribution, and metabolism studies of 64Cu-DOTA-cetuximab, a PET-imaging agent for epidermal growth-factor receptor-positive tumors,” Cancer Biotherapy and Radiopharmaceuticals, vol. 23, no. 2, pp. 158–171, 2008. View at Publisher · View at Google Scholar · View at Scopus
  41. M. Eiblmaier, L. A. Meyer, M. A. Watson, P. M. Fracasso, L. J. Pike, and C. J. Anderson, “Correlating EGFR expression with receptor-binding properties and internalization of 64Cu-DOTA-cetuximab in 5 cervical cancer cell lines,” Journal of Nuclear Medicine, vol. 49, no. 9, pp. 1472–1479, 2008. View at Publisher · View at Google Scholar · View at Scopus
  42. C. Yoshida, C. Sogawa, A. B. Tsuji et al., “Development of positron emission tomography imaging by 64Cu-labeled Fab for detecting ERC/mesothelin in a mesothelioma mouse model,” Nuclear Medicine Communications, vol. 31, no. 5, pp. 380–388, 2010. View at Publisher · View at Google Scholar · View at Scopus
  43. J. E. Mortimer, J. R. Bading, D. M. Colcher et al., “Functional imaging of human epidermal growth factor receptor 2-positive metastatic breast cancer using 64Cu-DOTA-trastuzumab PET,” Journal of Nuclear Medicine, vol. 55, no. 1, pp. 23–29, 2014. View at Publisher · View at Google Scholar · View at Scopus
  44. K. Tamura, H. Kurihara, K. Yonemori et al., “64Cu-DOTA-trastuzumab PET imaging in patients with HER2-positive breast cancer,” Journal of Nuclear Medicine, vol. 54, no. 11, pp. 1869–1875, 2013. View at Publisher · View at Google Scholar · View at Scopus
  45. C. J. Anderson, J. M. Connett, S. W. Schwarz et al., “Copper-64-labeled antibodies for PET imaging,” Journal of Nuclear Medicine, vol. 33, no. 9, pp. 1685–1691, 1992. View at Google Scholar · View at Scopus
  46. D. J. Slamon, G. M. Clark, S. G. Wong, W. J. Levin, A. Ullrich, and W. L. McGuire, “Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene,” Science, vol. 235, no. 4785, pp. 177–182, 1987. View at Publisher · View at Google Scholar · View at Scopus